Crossmark

Testosterone replacement therapy and the risk of adverse cardiovascular outcomes and mortality

Crossref DOI link: https://doi.org/10.1186/s12610-019-0085-7

Published Online: 2019-03-29

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pantalone, Kevin M. https://orcid.org/0000-0002-3897-4551
George, Joyce

Ji, Xinge

Kattan, Michael W.

Milinovich, Alex

Bauman, Janine M.

Burguera, Bartolome

Zimmerman, Robert S.

Misra-Hebert, Anita D.
License Information

Text and Data Mining valid from 2019-03-29
More Information

Article History

Received: 11 January 2019

Accepted: 26 February 2019

First Online: 29 March 2019

Ethics approval and consent to participate

: This research was approved by Cleveland Clinic’s Institutional Review Board. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: A waiver of informed consent was granted by the Cleveland Clinic’s Institutional Review Board.

: We confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.